NO944930L - Hemming av dysfunksjonell uterin blödning - Google Patents

Hemming av dysfunksjonell uterin blödning

Info

Publication number
NO944930L
NO944930L NO944930A NO944930A NO944930L NO 944930 L NO944930 L NO 944930L NO 944930 A NO944930 A NO 944930A NO 944930 A NO944930 A NO 944930A NO 944930 L NO944930 L NO 944930L
Authority
NO
Norway
Prior art keywords
uterine bleeding
dysfunctional uterine
inhibition
och2ch2
piperidone
Prior art date
Application number
NO944930A
Other languages
English (en)
Other versions
NO944930D0 (no
Inventor
Patrick Peter Keohane
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944930D0 publication Critical patent/NO944930D0/no
Publication of NO944930L publication Critical patent/NO944930L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Anvendelse av en forbindelse med formelen OCH2CH2¿R2 (I) hvor R1 og R3 uavhengig av hverandre er hydrogen, O O fl II -CH3, -C-(C1-C6-alkyl), eller -C-Ar. hvor Ar er eventuelt substituert fenyl; R2 er valgt fra gruppen bestående av pyrrolldlno og plperldlno; eller et farmasøytisk akseptabelt salt eller solvat derav, l fremstillingen av et medikament som er nyttig for hemming av dysfunksjonell uterin blødning.
NO944930A 1993-12-21 1994-12-19 Hemming av dysfunksjonell uterin blödning NO944930L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,391 US5446053A (en) 1993-12-21 1993-12-21 Methods of inhibiting dysfunctional uterine bleeding

Publications (2)

Publication Number Publication Date
NO944930D0 NO944930D0 (no) 1994-12-19
NO944930L true NO944930L (no) 1995-06-22

Family

ID=22623570

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944930A NO944930L (no) 1993-12-21 1994-12-19 Hemming av dysfunksjonell uterin blödning

Country Status (20)

Country Link
US (2) US5446053A (no)
EP (1) EP0659417B1 (no)
JP (1) JPH07215858A (no)
KR (1) KR950016726A (no)
CN (1) CN1109752A (no)
AT (1) ATE168887T1 (no)
AU (1) AU692490B2 (no)
CA (1) CA2138510A1 (no)
CZ (1) CZ321094A3 (no)
DE (1) DE69412049T2 (no)
DK (1) DK0659417T3 (no)
ES (1) ES2119094T3 (no)
GR (1) GR3027706T3 (no)
HU (1) HUT71469A (no)
IL (1) IL112037A (no)
NO (1) NO944930L (no)
NZ (1) NZ270167A (no)
PH (1) PH31099A (no)
RU (1) RU94044456A (no)
ZA (1) ZA9410080B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
ATE406909T1 (de) 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
CA2352461A1 (en) * 1998-11-26 2000-06-02 Tomohito Fujii Pharmaceutical composition for periodic administration
PT1175433E (pt) 1999-05-04 2005-11-30 Strakan Int Ltd Glicosidos androgenos e sua actividade androgenica
IN191020B (no) 2000-03-28 2003-09-13 Dabur Res Foundation
WO2002094268A1 (en) * 2001-05-22 2002-11-28 Eli Lilly And Company Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
DE60210283T2 (de) * 2001-05-22 2006-11-09 Eli Lilly And Co., Indianapolis 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren
MXPA04012419A (es) * 2002-06-25 2005-04-19 Wyeth Corp Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con la hormona.
KR102295878B1 (ko) 2021-06-16 2021-08-31 최경선 셀프용 등 지압기

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4859585A (en) * 1986-04-17 1989-08-22 Trustees Of Tufts College In-vitro methods for identifying compositions which are agonists and antagonists of estrogens
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
EP0659417B1 (en) 1998-07-29
RU94044456A (ru) 1996-10-10
NZ270167A (en) 1997-08-22
NO944930D0 (no) 1994-12-19
DE69412049T2 (de) 1999-01-14
GR3027706T3 (en) 1998-11-30
AU8156194A (en) 1995-06-29
CA2138510A1 (en) 1995-06-22
IL112037A (en) 1999-03-12
EP0659417A3 (en) 1995-09-06
ZA9410080B (en) 1996-06-19
ATE168887T1 (de) 1998-08-15
DK0659417T3 (da) 1998-12-07
CZ321094A3 (en) 1995-08-16
AU692490B2 (en) 1998-06-11
PH31099A (en) 1998-02-05
JPH07215858A (ja) 1995-08-15
US5552416A (en) 1996-09-03
HU9403663D0 (en) 1995-02-28
ES2119094T3 (es) 1998-10-01
CN1109752A (zh) 1995-10-11
HUT71469A (en) 1995-11-28
EP0659417A2 (en) 1995-06-28
US5446053A (en) 1995-08-29
KR950016726A (ko) 1995-07-20
DE69412049D1 (de) 1998-09-03
IL112037A0 (en) 1995-03-15

Similar Documents

Publication Publication Date Title
NO944930L (no) Hemming av dysfunksjonell uterin blödning
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
MY132056A (en) Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
MX9602837A (es) Composiciones cosmeticas o farmaceuticas que contienen mangiferina o sus derivados.
NO944927L (no) Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom
NO944914L (no) Fremgangsmåte for å inhibere autoimmunsykdommer
NO944934L (no) Hemming av vasomotoriske symptomer og tilhörende psykologiske forstyrrelser i forbindelse med post-menopausalt syndrom
NO944919L (no) Fremgangsmåte for å inhibere atrofi av huden eller vagina
DK0651999T3 (da) Fremgangsmåder til inhibering af livmoderfibrose
UA32427C2 (uk) Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань
NO944926L (no) Fremgangsmåter for å inhibere myeloperoksidaseaktivitet
TW360652B (en) Acryloyl substituted disstamycin derivatives, process for preparing them, and pharmaceutical composition comprising them
NO944924L (no) Fremgangsmåter for inhibering av Turner's syndrom
NZ516100A (en) Streptogramin derivatives, preparation and compositions containing them
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
NO972887L (no) Piperidineddiksyrederivater anvendelige som fibrinogen-antagonistmiddel
NO944923L (no) Hemming av vektökning eller indusering av vekttap
NO975580L (no) Fremgangsmåte for å inhibere melanom
NO944577L (no) Hemming av effekten av amyloidogene proteiner
NO981578L (no) FremgangsmÕte for hemming av plasminogenaktivatorhemmer I
NO971794L (no) Fremgangsmåte for hemming av tilstander forbundet med bradykinin
NO944909L (no) Fremgangsmåter for inhibering av mannlig infertilitet
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6
DK540589D0 (da) Pyrrolidinderivater
NO973103L (no) Fremgangsmåte for inhibering av veksthormoneffekter